Lexicon Pharmaceuticals Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 285

Employees

  • Stock Symbol
  • LXRX

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.99
  • (As of Friday Closing)

Lexicon Pharmaceuticals General Information

Description

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Contact Information

Formerly Known As
Lexicon Genetics, Lexicon Genetics Inc
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 2445 Technology Forest Boulevard
  • 11th Floor
  • The Woodlands, TX 77381
  • United States
+1 (281) 000-0000

Lexicon Pharmaceuticals Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lexicon Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.99 $2.09 $0.92 - $3.73 $719M 361M 2.7M -$0.83

Lexicon Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 527,006 260,930 254,891 479,932
Revenue 2,311 1,204 139 298
EBITDA (185,355) (171,196) (100,333) (86,798)
Net Income (193,582) (177,119) (101,944) (87,758)
Total Assets 417,219 229,429 194,299 136,909
Total Debt 106,244 106,064 55,294 2,279
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lexicon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lexicon Pharmaceuticals‘s full profile, request access.

Request a free trial

Lexicon Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commerciali
Pharmaceuticals
The Woodlands, TX
285 As of 2023
00.000
000000000 00.000

000000

niam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo co
0000000000000
Fremont, CA
000 As of 0000
00000
00.00 0000-00-00
000000&0 00000

000000

liquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupt
0000000000000
New York, NY
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lexicon Pharmaceuticals Competitors (113)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CymaBay Therapeutics Formerly VC-backed Fremont, CA 000 00000 000000&0 00000
Axsome Therapeutics Corporation New York, NY 000 00000 00000000 00000
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA 000 00000 000000&0
Amicus Therapeutics Formerly VC-backed Princeton, NJ 000 00000 000000000 00 00000
Blueprint Medicines Formerly VC-backed Cambridge, MA 000 00.000 000000000000 00.000
You’re viewing 5 of 113 competitors. Get the full list »

Lexicon Pharmaceuticals Patents

Lexicon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230330074-A1 Compounds and methods for treating spasticity Pending 15-Apr-2022 0000000000
US-20230357181-A1 Methods and compounds useful in the sythesis of an aak1 inhibitor Pending 01-Mar-2022 0000000000
US-20230357182-A1 Solid forms of (s)-1-((2',6-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof Pending 01-Mar-2022 0000000000
US-20220370485-A1 Compounds and methods for treating or preventing cardiovascular diseases and conditions Pending 14-Jan-2021 0000000000
US-20240100013-A1 Sotagliflozin for improving left atrial function Pending 04-Jan-2021 A61K31/351
To view Lexicon Pharmaceuticals’s complete patent history, request access »

Lexicon Pharmaceuticals Executive Team (22)

Name Title Board Seat
Mike Exton Chief Executive Officer & Director
Lonnel Coats Chief Executive Officer & Board Member
Jeffrey Wade JD Chief Financial Officer, Finance & President
Kristen Alexander Chief Accounting Officer, Accounting & Vice President
Tom Garner Senior Vice President & Chief Commercial Officer
You’re viewing 5 of 22 executive team members. Get the full list »

Lexicon Pharmaceuticals Board Members (10)

Name Representing Role Since
00000000000 000000 The Invus Group Board Member 000 0000
000000 00000 00 Self Board Member 000 0000
000000 00000 Lexicon Pharmaceuticals Chief Executive Officer & Board Member 000 0000
00000000 0000000 The Invus Group Board Member 000 0000
0000000 0000000 The Invus Group Chairman & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Lexicon Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lexicon Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lexicon Pharmaceuticals‘s full profile, request access.

Request a free trial

Lexicon Pharmaceuticals Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Symphony Icon 02-Aug-2010 0000000000 0000 Pharmaceuticals 000000 00
Symphony Icon 01-Jun-2007 00000 0000 Pharmaceuticals 000000 00
Coelacanth Chemical 12-Jul-2001 0000000000 0000 Pharmaceuticals 000000 00
DataWave Solutions Corporate Other Healthcare Technology Systems
To view Lexicon Pharmaceuticals’s complete investments and acquisitions history, request access »

Lexicon Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated February, 21, 2024

24.98 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Lexicon Pharmaceuticals’s complete esg history, request access »

Lexicon Pharmaceuticals FAQs

  • When was Lexicon Pharmaceuticals founded?

    Lexicon Pharmaceuticals was founded in 1995.

  • Who is the founder of Lexicon Pharmaceuticals?

    Allan Bradley Ph.D, Arthur Sands Ph.D, and Charles Hsu are the founders of Lexicon Pharmaceuticals.

  • Who is the CEO of Lexicon Pharmaceuticals?

    Mike Exton and Lonnel Coats are the CEOs of Lexicon Pharmaceuticals.

  • Where is Lexicon Pharmaceuticals headquartered?

    Lexicon Pharmaceuticals is headquartered in The Woodlands, TX.

  • What is the size of Lexicon Pharmaceuticals?

    Lexicon Pharmaceuticals has 285 total employees.

  • What industry is Lexicon Pharmaceuticals in?

    Lexicon Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Lexicon Pharmaceuticals a private or public company?

    Lexicon Pharmaceuticals is a Public company.

  • What is Lexicon Pharmaceuticals’s stock symbol?

    The ticker symbol for Lexicon Pharmaceuticals is LXRX.

  • What is the current stock price of Lexicon Pharmaceuticals?

    As of 19-Jul-2024 the stock price of Lexicon Pharmaceuticals is $1.99.

  • What is the current market cap of Lexicon Pharmaceuticals?

    The current market capitalization of Lexicon Pharmaceuticals is $719M.

  • What is Lexicon Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Lexicon Pharmaceuticals is $2.31M.

  • Who are Lexicon Pharmaceuticals’s competitors?

    CymaBay Therapeutics, Axsome Therapeutics, ACADIA Pharmaceuticals, Amicus Therapeutics, and Blueprint Medicines are some of the 113 competitors of Lexicon Pharmaceuticals.

  • What is Lexicon Pharmaceuticals’s annual earnings per share (EPS)?

    Lexicon Pharmaceuticals’s EPS for 12 months was -$0.83.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »